MARKET

ONCY

ONCY

Oncolytics Biotech Inc
NASDAQ
0.8330
-0.0205
-2.40%
Opening 13:06 02/12 EST
OPEN
0.8500
PREV CLOSE
0.8535
HIGH
0.8598
LOW
0.8190
VOLUME
568.99K
TURNOVER
--
52 WEEK HIGH
1.510
52 WEEK LOW
0.3258
MARKET CAP
89.64M
P/E (TTM)
-2.9560
1D
5D
1M
3M
1Y
5Y
1D
Analysts’ Top Healthcare Picks: Oncolytics Biotech (ONCY), NeuroPace (NPCE)
TipRanks · 3d ago
Weekly Report: what happened at ONCY last week (0202-0206)?
Weekly Report · 3d ago
Analysts Offer Insights on Healthcare Companies: Insmed (INSM), Oncolytics Biotech (ONCY) and Imunon (IMNN)
TipRanks · 6d ago
Oncolytics Biotech Appoints John McAdory and Yujun Wu to Leadership Team
Reuters · 02/05 14:26
Stocks in play: Oncolytics Biotech Inc
Barchart · 02/05 08:37
$207B Market Shift: The Race for Fast Track Approval in Oncology
Barchart · 02/05 08:35
Oncolytics Biotech receives FDA Fast Track for pelareorep
TipRanks · 02/04 17:28
Pelareorep Platform Breakthrough Drives $10 Target and Buy Rating on Oncolytics Biotech
TipRanks · 02/04 17:06
More
About ONCY
Oncolytics Biotech Inc. is a clinical-stage biotechnology company developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. It acts by inducing anti-cancer immune responses and promotes an inflamed tumor phenotype, turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. The Company is also advancing its programs in hormone receptor-positive / human epidermal growth factor 2-negative (HR+/ HER2-) advanced and metastatic breast cancer (mBC) and metastatic pancreatic ductal adenocarcinoma (PDAC) to registration-enabled clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

Webull offers Oncolytics Biotech Inc stock information, including NASDAQ: ONCY real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ONCY stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ONCY stock methods without spending real money on the virtual paper trading platform.